Back to News
Market Impact: 0.18
Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Scienture Holdings subsidiary Scienture, LLC entered a distribution agreement to expand U.S. commercial access for REZENOPY Nasal Spray 10 mg across addiction treatment centers. The agreement supports broader product reach in a targeted treatment channel, though no financial terms, sales projections, or revenue impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SCNX0.55
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Trump Says US Team Met With Iranians at UNGA
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Heidi CEO on AI in Healthcare, $900M valuation
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction
- What Is an AI Investment Research Platform?